Delivery of oligonucleotide-based therapeutics: challenges and opportunities. (2021)
Attributed to:
Peptide conjugated oligonucleotides for a phase I/IIa clinical trial in Spinal Muscular Atrophy
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.15252/emmm.202013243
PubMed Identifier: 33821570
Publication URI: http://europepmc.org/abstract/MED/33821570
Type: Journal Article/Review
Volume: 13
Parent Publication: EMBO molecular medicine
Issue: 4
ISSN: 1757-4676